A listed pharmaceutical company with $5 Billion of assets under management has become a high-tech pharmaceutical health industry cluster that covers manufacturing, R&D, and sales in the pharmaceutical area after 2 decades of arduous efforts. The firm is open to global R&D partnerships and investment opportunities.
The firm has a focused interest in finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services. In addition, the firm pays special attention to novel therapeutic innovations in sepsis, anti-infection, and oncology area.
The firm has no specific company or management team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply